148 related articles for article (PubMed ID: 30149128)
41. Drug Delivery Strategies to Overcome the Blood-Brain Barrier (BBB).
Helms HCC; Kristensen M; Saaby L; Fricker G; Brodin B
Handb Exp Pharmacol; 2022; 273():151-183. PubMed ID: 33367937
[TBL] [Abstract][Full Text] [Related]
42. Paclitaxel-2'-Ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity.
Tanino T; Nawa A; Kondo E; Kikkawa F; Daikoku T; Tsurumi T; Luo C; Nishiyama Y; Takayanagi Y; Nishimori K; Ichida S; Wada T; Miki Y; Iwaki M
Pharm Res; 2007 Mar; 24(3):555-65. PubMed ID: 17245652
[TBL] [Abstract][Full Text] [Related]
43. Sodium-Dependent Neutral Amino Acid Transporter 2 Can Serve as a Tertiary Carrier for l-Type Amino Acid Transporter 1-Utilizing Prodrugs.
Huttunen J; Kronenberger T; Montaser AB; Králová A; Terasaki T; Poso A; Huttunen KM
Mol Pharm; 2023 Feb; 20(2):1331-1346. PubMed ID: 36688491
[TBL] [Abstract][Full Text] [Related]
44. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.
Peura L; Malmioja K; Laine K; Leppänen J; Gynther M; Isotalo A; Rautio J
Mol Pharm; 2011 Oct; 8(5):1857-66. PubMed ID: 21770378
[TBL] [Abstract][Full Text] [Related]
45. A Minireview: Usefulness of Transporter-Targeted Prodrugs in Enhancing Membrane Permeability.
Murakami T
J Pharm Sci; 2016 Sep; 105(9):2515-2526. PubMed ID: 27321236
[TBL] [Abstract][Full Text] [Related]
46. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
47. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
48. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
[TBL] [Abstract][Full Text] [Related]
49. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
50. L-Type amino acid transporter 1 as a target for drug delivery.
Puris E; Gynther M; Auriola S; Huttunen KM
Pharm Res; 2020 May; 37(5):88. PubMed ID: 32377929
[TBL] [Abstract][Full Text] [Related]
51. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
Arora A; Seth K; Kalra N; Shukla Y
Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
[TBL] [Abstract][Full Text] [Related]
52. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
[TBL] [Abstract][Full Text] [Related]
53. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
54. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
Komatani H; Kotani H; Hara Y; Nakagawa R; Matsumoto M; Arakawa H; Nishimura S
Cancer Res; 2001 Apr; 61(7):2827-32. PubMed ID: 11306452
[TBL] [Abstract][Full Text] [Related]
55. Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1).
Kongpracha P; Nagamori S; Wiriyasermkul P; Tanaka Y; Kaneda K; Okuda S; Ohgaki R; Kanai Y
J Pharmacol Sci; 2017 Feb; 133(2):96-102. PubMed ID: 28242177
[TBL] [Abstract][Full Text] [Related]
56. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.
Huisman MT; Chhatta AA; van Tellingen O; Beijnen JH; Schinkel AH
Int J Cancer; 2005 Sep; 116(5):824-9. PubMed ID: 15849751
[TBL] [Abstract][Full Text] [Related]
57. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
58. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
59. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.
Li C; Guan X; Xue H; Wang P; Wang M; Gai X
Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760
[TBL] [Abstract][Full Text] [Related]
60. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells.
Nanayakkara AK; Follit CA; Chen G; Williams NS; Vogel PD; Wise JG
Sci Rep; 2018 Jan; 8(1):967. PubMed ID: 29343829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
